Table 4 |
||||
|
Results from Multiple Logistic Regression |
||||
| Outcome |
Factor |
B (S.E.) |
P value |
Odds Ratio |
|
|
||||
| HIV-AIDS N = 804 |
Effectiveness |
.476 (.128) |
.000 |
1.61 |
| Safety |
.318 (.111) |
.004 |
1.37 |
|
| Knowledge |
.276 (.089) |
.002 |
1.318 |
|
| Anxiety |
-.033 (.102) |
.745 |
0.97 |
|
| Not in Opposition |
.166 (.121) |
.172 |
1.18 |
|
| HEP C N = 776 |
Effectiveness |
.603 (.143) |
.000 |
1.83 |
| Safety |
.470 (.128) |
.000 |
1.60 |
|
| Knowledge |
.273 (.106) |
.010 |
1.31 |
|
| Anxiety |
.116 (.124) |
.349 |
1.12 |
|
| Not in Opposition |
.251 (.144) |
.080 |
1.29 |
|
| FLU N = 818 |
Effectiveness |
.250 (.114) |
.029 |
1.28 |
| Safety |
.209 (.102) |
.039 |
1.23 |
|
| Knowledge |
.215 (.074) |
.004 |
1.24 |
|
| Anxiety |
.099 (.088) |
.256 |
1.10 |
|
| Not in Opposition |
.040 (.107) |
.707 |
1.04 |
|
|
|
||||
|
Ritvo et al. Journal of Immune Based Therapies and Vaccines 2003 1:3 doi:10.1186/1476-8518-1-3 |
||||
